
CLAIMS


~~1. Use of a compound having the formula:~~



~~or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pigmented villonodular synovitis (PVNS), tenosynovial giant cell tumor (TGCT), plexiform neurofibromas, or malignant peripheral nerve sheath tumors (MPNST) in a subject; wherein if the subject suffers from MPNST, the medicament is for administration in combination with sirolimus.~~


~~2. The use according to claim 1, wherein the subject suffers from pigmented villonodular synovitis (PVNS) or tenosynovial giant cell tumor (TGCT).~~

1~~3~~. ~~The use of claim 1,~~ Use of a compound having the formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of tenosynovial giant cell tumor ~~wherein the subject suffers from~~ (TGCT).

2~~4~~. ~~The use of claim 1,~~ Use of a compound having the formula:




or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of pigmented villonodular synovitis ~~wherein the subject suffers from~~ (PVNS).

~~5. The use of claim 1, wherein the subject suffers from metastasis of TGCT.~~


~~6. The use of claim 1, wherein the subject suffers from metastasis of PNVS.~~

3~~7~~. ~~The use according to claim 1,~~ Use of a compound having the formula:



in the manufacture of a medicament for the treatment of ~~wherein the subject suffers from~~ plexiform neurofibromas.

4~~8~~. ~~The use of claim 1,~~ Use of a compound having the formula:



or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for the treatment of ~~wherein the subject suffers from~~ malignant peripheral nerve sheath tumors

(MPNST), wherein if the subject suffers from MPNST, the medicament is for administration in combination with sirolimus.~~.~~

5~~9~~. The use of any one of claims 1 to ~~8~~4, wherein the medicament is formulated for oral administration.